Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Witzig, Thomas E., Tang, Hui, Micallef, Ivana N. M., Ansell, Stephen M., Link, Brian K., Inwards, David J., Porrata, Luis F., Johnston, Patrick B., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Thompson, Carrie A., Allmer, Cristine, Maurer, Matthew J., Gupta, Mamta, Weiner, George, Hohl, Ray, Kurtin, Paul J., Ding, Husheng, Loegering, David, Schneider, Paula, Peterson, Kevin, Habermann, Thomas M., Kaufmann, Scott H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208296/
https://ncbi.nlm.nih.gov/pubmed/21725056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-334904
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados